Breast Cancer
Showing NaN - NaN of 191
Breast Cancer Trial in Seoul (Extracorporeal shock waves)
Recruiting
- Breast Cancer
- Extracorporeal shock waves
-
Seoul, Yangcheon Gu, Korea, Republic ofKiwhan Kim
Oct 25, 2022
Breast Cancer, Survivorship, Quality of Life Trial in Seoul (Shared decision making, Usual care)
Enrolling by invitation
- Breast Cancer
- +2 more
- Shared decision making
- Usual care
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 13, 2022
Ovarian Cancer, Breast Cancer Trial in Worldwide (Olaparib)
Enrolling by invitation
- Ovarian Cancer
- Breast Cancer
-
Boca Raton, Florida
- +98 more
Aug 22, 2022
Breast Cancer Trial in Worldwide (Amcenestrant, Tamoxifen, Amcenestrant-matching )
Active, not recruiting
- Breast Cancer
- Amcenestrant
- +3 more
-
East Syracuse, New York
- +52 more
Aug 18, 2022
Mesothelioma, Glioblastoma, Renal Cell Carcinoma Trial in Korea, Republic of, Taiwan, United States (NGM707, NGM707 plus
Recruiting
- Mesothelioma
- +14 more
- NGM707
- NGM707 plus pembrolizumab
-
Los Angeles, California
- +13 more
Aug 16, 2022
Breast Cancer Trial in Worldwide (Trastuzumab deruxtecan, Capecitabine, Lapatinib)
Active, not recruiting
- Breast Cancer
- Trastuzumab deruxtecan
- +3 more
-
Chandler, Arizona
- +226 more
Aug 11, 2022
Breast Cancer Trial in Seoul (robot assisted nipple sparing mastectomy(RNSM), Conventional nipple sparing mastectomy(CNSM))
Not yet recruiting
- Breast Cancer
- robot assisted nipple sparing mastectomy(RNSM)
- Conventional nipple sparing mastectomy(CNSM)
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Aug 5, 2022
Breast Cancer Trial in Worldwide (Abemaciclib, Anastrozole, Letrozole)
Breast Cancer Trial in Worldwide (biological, drug, other, procedure)
Active, not recruiting
- Breast Cancer
- nivolumab
- +6 more
-
Mobile, Alabama
- +255 more
Jul 21, 2022
Breast Cancer Trial in Worldwide (Elacestrant, Standard of Care)
Active, not recruiting
- Breast Cancer
- Elacestrant
- Standard of Care
-
Tucson, Arizona
- +167 more
Jul 19, 2022
HER2 Low and Describe SoC, Treatment Patterns, and Outcome in
Completed
- Breast Cancer
- None (Observational study)
-
Pittsburgh, Pennsylvania
- +12 more
May 25, 2022
Breast Cancer Trial in Worldwide (Amcenestrant-matching , SAR439859, Palbociclib)
Active, not recruiting
- Breast Cancer
- Amcenestrant-matching placebo
- +5 more
-
Daphne, Alabama
- +299 more
May 5, 2022
Breast Cancer Trial in Worldwide (Trastuzumab deruxtecan (T-DXd), Ado-trastuzumab emtansine (T-DM1))
Active, not recruiting
- Breast Cancer
- Trastuzumab deruxtecan (T-DXd)
- Ado-trastuzumab emtansine (T-DM1)
-
Los Angeles, California
- +163 more
Apr 1, 2022
Breast Cancer Trial in Worldwide (Palbociclib, Standard Adjuvant Endocrine Therapy)
Active, not recruiting
- Breast Cancer
- Palbociclib
- Standard Adjuvant Endocrine Therapy
-
Mobile, Alabama
- +437 more
Mar 21, 2022
Breast Cancer Trial in Seoul
Not yet recruiting
- Breast Cancer
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 23, 2022
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer Trial in China, Korea, Republic of, Taiwan (ZW25, Docetaxel,
Active, not recruiting
- Breast Cancer
- +2 more
- ZW25
- +4 more
-
Beijing, Beijing, China
- +21 more
Apr 1, 2022
Breast Cancer Trial in Worldwide (Trastuzumab Emtansine)
Completed
- Breast Cancer
- Trastuzumab Emtansine
-
Buenos Aires, Argentina
- +299 more
Mar 31, 2022
Breast Cancer, Mastectomy, Pain, Chronic Trial in Seoul (Opioid-free anesthesia, Conventional opioid-based anesthesia)
Recruiting
- Breast Cancer
- +3 more
- Opioid-free anesthesia
- Conventional opioid-based anesthesia
-
Seoul, Korea, Republic ofGangnam Severance Hospital
Mar 24, 2022
Breast Cancer Trial in Seoul (PECs block, Not receiving PECs Block)
Recruiting
- Breast Cancer
- PECs block
- Not receiving PECs Block
-
Seoul, Korea, Republic ofYoung Song
Mar 3, 2022
Breast Cancer Trial in Worldwide (trastuzumab, docetaxel, lapatinib ditosylate)
Active, not recruiting
- Breast Cancer
- trastuzumab
- +3 more
-
Anchorage, Alaska
- +257 more
Feb 28, 2022